Table 3. PR and Ki-67 LIs before and after the letrozole treatment according to clinicopathological factors in 10 DCIS cases examined.
| |
|
Aromatase immunoreactivity at baseline |
|
|
|---|---|---|---|---|
| Parameter | Evaluation point | + (n=5) | − (n=5) | P-value |
| PR LI | Baseline | 84 (0–100) | 95 (0–100) | 0.83 |
| |
Post-treatment |
36 (0–83) |
6 (0–66) |
0.68 |
| Ki-67 LI | Baseline | 7 (4–24) | 10 (8–18) | 0.46 |
| Post-treatment | 1 (0–4) | 4 (3–7) | 0.035 | |
| |
|
Post-treatment diagnosis |
|
|
|---|---|---|---|---|
| Parameter | Evaluation point | DCIS (n=7) | IDC (n=3) | P-value |
| PR LI | Baseline | 84 (0–100) | 95 (90–100) | 0.36 |
| |
Post-treatment |
6 (0–83) |
30 (3–36) |
0.91 |
| Ki-67 LI | Baseline | 10 (4–24) | 12 (7–18) | 0.57 |
| Post-treatment | 3 (0–4) | 5 (1–7) | 0.26 | |
| |
|
Period of letrozole treatment |
|
|
|---|---|---|---|---|
| Parameter | Evaluation point | Shorter (n=5) | Longer (n=5) | P-value |
| PR LI | Baseline | 84 (0–100) | 95 (0–100) | 0.83 |
| |
Post-treatment |
58 (0–83) |
6 (0–36) |
0.4 |
| Ki-67 LI | Baseline | 10 (4–24) | 10 (7–18) | 0.83 |
| Post-treatment | 2 (0–4) | 4 (1–7) | 0.14 | |
Data represent the median (min–max). The statistical analyses were performed using a Mann–Whitney U-test. P-value <0.05 was considered significant, and given in bold.